Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956447 · ClinicalTrials.gov registry record · Phase 2
Administration of Kisspeptin in Patients With Hyperprolactinemia
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02956447: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02956447 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02956447, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The goal of this study is to learn more about how kisspeptin, a naturally occurring hormone, affects women with high levels of prolactin (also called hyperprolactinemia). Subjects in one group will undergo blood sampling every 10 minutes over two 12-hour periods (one 12-hour period without any intervention and one 12-hour period with intravenous (IV) kisspeptin administration). Subjects in the second group will receive subcutaneous (SC) kisspeptin every 90 minutes for eight days.
Interventions
- DRUG Kisspeptin 112-121
- DRUG GnRH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-11-17 |
| Est. Completion | 2023-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956447
The ClinicalTrials.gov registry entry for NCT02956447 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Kisspeptin 112-121 is the first listed.
NCT02956447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956447 about?
NCT02956447 is a clinical study titled "Administration of Kisspeptin in Patients With Hyperprolactinemia". The goal of this study is to learn more about how kisspeptin, a naturally occurring hormone, affects women with high levels of prolactin (also called hyperprolactinemia). Subjects in one group will undergo blood sampling every 10 minutes over two 12-hour periods (one 12-hour period without any inter...
What is the current status of trial NCT02956447?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-11-17. Estimated completion is 2023-07-29.
What interventions are being tested in trial NCT02956447?
The interventions under investigation include: Kisspeptin 112-121 (DRUG), GnRH (DRUG).
Who is sponsoring clinical trial NCT02956447?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.